검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose)) Daiichi Sankyo·Non-Small Cell Lung Cancer Metasta… ORR 64%·t½ 53 h |
|---|---|
Overview Program | Patritumab Deruxtecan (Fixed dose) |
Overview Company | Daiichi Sankyo |
Overview Modality | ADC |
Overview Target | Non-Small Cell Lung Cancer Metastatic |
Overview Indication | Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | inhibits human epidermal growth factor receptor 2 (HER2) while sparing wild-type epidermal growth factor receptor |
MoA Biomarker | Biomarker of Methylthioadenosine Phosphorylase-Selective Protein Arginine Methyltransferase 5 Inhibition |
PK/PD Half-life | 53 h |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial.. Contemporary data show an increasing incidence of venous thromboembolism in children, yet there are few evidence-based treatment guidelines on direct oral anticoagulant use for venous thromboembolism in this population. We aimed to investigate th… |
Clinical Primary efficacy | ORR 64% |
Clinical ORR | 56% |
Clinical PFS | 5.5 |
Clinical Result source | ClinicalTrials.gov NCT04619004 |
Clinical Data Tier / Score | A · 61 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose)) Daiichi Sankyo·Non-Small Cell Lung Cancer Metasta… ORR 64%·t½ 53 h |
|---|---|
Overview Program | Patritumab Deruxtecan (Fixed dose) |
Overview Company | Daiichi Sankyo |
Overview Modality | ADC |
Overview Target | Non-Small Cell Lung Cancer Metastatic |
Overview Indication | Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | inhibits human epidermal growth factor receptor 2 (HER2) while sparing wild-type epidermal growth factor receptor |
MoA Biomarker | Biomarker of Methylthioadenosine Phosphorylase-Selective Protein Arginine Methyltransferase 5 Inhibition |
PK/PD Half-life | 53 h |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial.. Contemporary data show an increasing incidence of venous thromboembolism in children, yet there are few evidence-based treatment guidelines on direct oral anticoagulant use for venous thromboembolism in this population. We aimed to investigate th… |
Clinical Primary efficacy | ORR 64% |
Clinical ORR | 56% |
Clinical PFS | 5.5 |
Clinical Result source | ClinicalTrials.gov NCT04619004 |
Clinical Data Tier / Score | A · 61 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교